313 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LGND Ligand Pharmaceuticals Incorporated $253.56 $5.35B N/A
Article Searches
This Future Clinical Endpoint Could Make An Instant Blockbuster Out Of Viking's VK5211 https://seekingalpha.com/article/4211533-future-clinical-endpoint-make-instant-blockbuster-vikings-vk5211?source=feed_sector_healthcare Oct 15, 2018 - Hip fracture is a serious and growing healthcare problem that is in desperate need of focus.1-year mortality rates in patients post hip fracture repair are high and need to be addressed.Improvements i
bluebird's MAA for LentiGlobin Gene Therapy Accepted by EMA http://www.zacks.com/stock/news/326648/bluebirds-maa-for-lentiglobin-gene-therapy-accepted-by-ema?cid=CS-ZC-FT-326648 Oct 08, 2018 - bluebird's marketing authorization application (MAA) for its experimental gene therapy, LentiGlobin, was accepted by the regulatory body in Europe.
Zacks.com highlights: MCBC Holdings, Newpark Resources, Cigna, Weight Watchers International and Ligand Pharmaceuticals http://www.zacks.com/stock/news/326464/zackscom-highlights-mcbc-holdings-newpark-resources-cigna-weight-watchers-international-and-ligand-pharmaceuticals?cid=CS-ZC-FT-326464 Oct 05, 2018 - Zacks.com highlights: MCBC Holdings, Newpark Resources, Cigna, Weight Watchers International and Ligand Pharmaceuticals
Alnylam Files Clinical Trial Application for ALN-AAT02 in UK http://www.zacks.com/stock/news/326341/alnylam-files-clinical-trial-application-for-aln-aat02-in-uk?cid=CS-ZC-FT-326341 Oct 04, 2018 - Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.
VistaGen Up on Fast Track Designation to Pain Candidate http://www.zacks.com/stock/news/326229/vistagen-up-on-fast-track-designation-to-pain-candidate?cid=CS-ZC-FT-326229 Oct 04, 2018 - VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.
Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo http://www.zacks.com/stock/news/326091/amgen-gets-fda-nod-for-once-weekly-regimen-of-kyprolis-combo?cid=CS-ZC-FT-326091 Oct 03, 2018 - Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).
Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara http://www.zacks.com/stock/news/326044/paratek-prtk-gets-fda-approval-for-nuzyra-and-seysara?cid=CS-ZC-FT-326044 Oct 03, 2018 - Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.
Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce http://www.zacks.com/stock/news/325709/insmed-insm-wins-fda-nod-for-lung-disease-drug-arikayce?cid=CS-ZC-FT-325709 Oct 01, 2018 - Insmed's (INSM) lung infection drug Arikayce gains an accelerated approval from the FDA for the treatment of lung disease caused by mycobacterium avium complex (MAC).
Ultragenyx Reports Top-line Data From Gene Therapy Candidate http://www.zacks.com/stock/news/325488/ultragenyx-reports-top-line-data-from-gene-therapy-candidate?cid=CS-ZC-FT-325488 Sep 28, 2018 - Ultragenyx (RARE) reports encouraging top-line data from two cohorts of the study evaluating its adeno-associated virus ("AAV") gene therapy candidate -- DTX301.
Time to Focus on Ligand Pharmaceuticals (LGND) for Strong Earnings Growth Potential http://www.zacks.com/stock/news/325180/time-to-focus-on-ligand-pharmaceuticals-lgnd-for-strong-earnings-growth-potential?cid=CS-ZC-FT-325180 Sep 27, 2018 - Ligand Pharmaceuticals (LGND) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

Pages: 123456...32

Page 1>

Related Companies

Name Exchange Price Mkt Cap
UTHR United Therapeutics Corporation NASDAQ $125.98 $5.49B
FGEN FibroGen, Inc NASDAQ $56.85 $4.79B
RDY Dr. Reddy's Laboratories Ltd NYSE $35.7 $5.93B
GLPG Galapagos NV NASDAQ $115.62 $5.94B
LOXO Loxo Oncology, Inc. NASDAQ $155.495 $4.74B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Ligand Pharmaceuticals Incorporated